Cas:473836-97-4 (E)-tert-Butyl 4-(2-ethoxy-2-oxoethylidene)azepane-1-carboxylate manufacturer & supplier

We serve Chemical Name:(E)-tert-Butyl 4-(2-ethoxy-2-oxoethylidene)azepane-1-carboxylate CAS:473836-97-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

(E)-tert-Butyl 4-(2-ethoxy-2-oxoethylidene)azepane-1-carboxylate

Chemical Name:(E)-tert-Butyl 4-(2-ethoxy-2-oxoethylidene)azepane-1-carboxylate
CAS.NO:473836-97-4
Synonyms:(E)-tert-Butyl 4-(2-ethoxy-2-oxoethylidene)azepane-1-carboxylate
Molecular Formula:C15H25NO4
Molecular Weight:283.3633
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:
Exact Mass:
LogP:

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like (E)-tert-Butyl 4-(2-ethoxy-2-oxoethylidene)azepane-1-carboxylate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(E)-tert-Butyl 4-(2-ethoxy-2-oxoethylidene)azepane-1-carboxylate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(E)-tert-Butyl 4-(2-ethoxy-2-oxoethylidene)azepane-1-carboxylate Use and application,(E)-tert-Butyl 4-(2-ethoxy-2-oxoethylidene)azepane-1-carboxylate technical grade,usp/ep/jp grade.


Related News: Natural Biogenex, a 100 per cent subsidiary of Natural Capsules, is speeding up its efforts to manufacture active pharmaceutical ingredients (APIs) following the recent grant from Union government’s production linked incentive (PLI) scheme to offset the import dependence. 2,4-dimethylpent-2-ene manufacturers Israel was a world leader in the vaccination rollout, with many seniors getting their shots in December, January and February as they were regarded as the most vulnerable sector of the population. 3-(2-Bromophenyl)-5-(2,4-dichlorophenyl)-1,2,4-oxadiazole suppliers After a four-year battle over a cancer drug patent, Novartis has been ordered by a California judge to pay a Daiichi Sankyo subsidiary $177.8 million. 14,17-Dihydroxypregn-4-ene-3,20-dione vendor & factory.